Geoffrey Barnes

List of Publications by Citations

142 papers	3,709 citations	19 h-index	59 g-index
177 ext. papers	4,851 ext. citations	5.5 avg, IF	5.64 L-index

#	Paper	IF	Citations
142	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 75, 2950-2973	15.1	1682
141	National Trends in Ambulatory Oral Anticoagulant Use. *American Journal of Medicine*, **2015**, 128, 1300-5.e2	4	407
140	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 72-81	5.1	266
139	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. *Thrombosis and Haemostasis*, **2020**, 120, 1004-1024	7	147
138	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. *Circulation*, **2019**, 140, e774-e801	16.7	93
137	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1154-6	15.4	88
136	Prevalence of and Factors Associated With Patient Nondisclosure of Medically Relevant Information to Clinicians. *JAMA Network Open*, **2018**, 1, e185293	10.4	57
135	Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants. *Circulation: Cardiovascular Quality and Outcomes*, **2016**, 9, 182-5	5.8	52
134	Diversity in the Pulmonary Embolism Response Team Model: An Organizational Survey of the National PERT Consortium Members. *Chest*, **2016**, 150, 1414-1417	5.3	48
133	Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. *Thrombosis and Haemostasis*, **2017**, 117, 246-251	7	37
132	Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and	2.4	33
131	The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. *Thrombosis Research*, **2014**, 134, 294-9	8.2	28
130	EVALUATING THE ROLE OF ANTICOAGULATION CLINICAL PHARMACISTS FOR COORDINATING PERIPROCEDURAL ANTICOAGULATION. *Journal of the American College of Cardiology*, **2017**, 69, 2488	15.1	26
129	The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. *Journal of Thrombosis and Thrombolysis*, **2020**, 49, 636-643	5.1	26
128	Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. *JAMA Network Open*, **2021**, 4, e2111788	10.4	25
127	Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. *JAMA Internal Medicine*, **2019**, 179, 533-541	11.5	23
126	Stroke and thromboembolism prevention in atrial fibrillation. *Heart*, **2020**, 106, 10-17	5.1	23

125	EXPRESS: A Multidisciplinary Pulmonary Embolism Response Team (PERT) - Experience from a national multicenter consortium. *Pulmonary Circulation*, **2019**, 2045894018824563	2.7	22
124	Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT Consortium members. *Hospital Practice (1995)*, **2017**, 45, 76-80	2.2	20
123	Evaluation of a pharmacist-led outpatient direct oral anticoagulant service. *American Journal of Health-System Pharmacy*, **2017**, 74, 483-489	2.2	18
122	National trends in venous disease. *Journal of Vascular Surgery*, **2010**, 51, 1467-73	3.5	18
121	Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. *Vascular Medicine*, **2015**, 20, 143-52	3.3	17
120	Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, **2021**, 9, 23-35	3.2	17
119	Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. *Implementation Science*, **2017**, 12, 87	8.4	16
118	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. *Journal of Thrombosis and Thrombolysis*, **2017**, 43, 283-288	5.1	15
117	Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. *JAMA Internal Medicine*, **2021**, 181, 817-824	11.5	15
116	Direct oral anticoagulants: unique properties and practical approaches to management. *Heart*, **2016**, 102, 1620-6	5.1	15
115	The impact of a multi-specialty team for high risk pulmonary embolism on resident and fellow education. *Vascular Medicine*, **2018**, 23, 372-376	3.3	15
114	Structure and function of anticoagulation clinics in the United States: an AC forum membership survey. *Journal of Thrombosis and Thrombolysis*, **2018**, 46, 7-11	5.1	14
113	Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. *Progress in Cardiovascular Diseases*, **2018**, 60, 600-606	8.5	14
112	Engaging with quality improvement in anticoagulation management. *Journal of Thrombosis and Thrombolysis*, **2015**, 39, 403-9	5.1	13
111	Venous thromboembolism: A clinician update. *Vascular Medicine*, **2019**, 24, 122-131	3.3	12
110	Endovascular iliocaval reconstruction for the treatment of iliocaval thrombosis: From imaging to intervention. *Vascular Medicine*, **2018**, 23, 267-275	3.3	12
109	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. *Journal of Thrombosis and Thrombolysis*, **2018**, 46, 39-49	5.1	12
108	Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. *Annals of Pharmacotherapy*, **2019**, 53, 21-27	2.9	12

107	Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). *Journal of Thrombosis and Thrombolysis*, **2013**, 35, 10-4	5.1	12
106	Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams. *JAMA Network Open*, **2020**, 3, e2010779	10.4	12
105	Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)). *Journal of Thrombosis and Thrombolysis*, **2014**, 37, 171-6	5.1	11
104	Dual antiplatelet agent failure: a new syndrome or clinical nonentity?. *American Heart Journal*, **2007** , 154, 732-5	4.9	11
103	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. *Seminars in Thrombosis and Hemostasis*, **2016**, 42, 662-70	5.3	11
102	SAMe-TTR predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI experience. *Vascular Medicine*, **2017**, 22, 197-203	3.3	10
101	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	10
100	Extended International Normalized Ratio testing intervals for warfarin-treated patients. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1307-1312	15.4	10
99	Bridging Anticoagulation Before Colonoscopy: Results of a Multispecialty Clinician Survey. *JAMA Cardiology*, **2016**, 1, 1076-1077	16.2	9
98	Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation. *American Journal of Cardiology*, **2016**, 117, 54-60	3	9
97	Assessment of Patient Nondisclosures to Clinicians of Experiencing Imminent Threats. *JAMA Network Open*, **2019**, 2, e199277	10.4	9
96	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. *Journal of Thrombosis and Thrombolysis*, **2018**, 46, 316-324	5.1	9
95	Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis. *American Heart Journal*, **2019**, 214, 158-166	4.9	8
94	Cardiac Rehabilitation Use After Percutaneous Coronary Intervention. *Journal of the American College of Cardiology*, **2019**, 73, 3148-3152	15.1	8
93	Urinary cyclic AMP in the switch process from depression to mania. *British Journal of Psychiatry*, **1974**, 125, 457-8	5.4	8
92	Combining antiplatelet and anticoagulant therapy in cardiovascular disease. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 642-648	3.1	8
91	Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. *Journal of the American College of Cardiology*, **2020**, 76, 2142-2154	15.1	8
90	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. *Annals of Internal Medicine*, **2021**, 174, 910-919	8	8

89	Cancer-Associated Venous Thromboembolism. *Current Treatment Options in Cardiovascular Medicine*, **2016**, 18, 23	2.1	8
88	Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative. *Vascular Medicine*, **2019**, 24, 153-155	3.3	7
87	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. *American Journal of Medicine*, **2020**, 133 Suppl 1, 1-27	2.4	7
86	Venous Thromboembolism Research Priorities: A Scientific Statement From the American Heart Association and the International Society on Thrombosis and Haemostasis. *Circulation*, **2020**, 142, e85-e94	16.7	7
85	Periprocedural Bridging Anticoagulation: Measuring the Impact of a Clinical Trial on Care Delivery. *American Journal of Medicine*, **2019**, 132, 109.e1-109.e7	2.4	6
84	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 2132-3	15.4	6
83	Anticoagulation: where we are and where we need to go. *Journal of Thrombosis and Thrombolysis*, **2009**, 28, 220-3	5.1	6
82	A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. *Blood Advances*, **2020**, 4, 6259-6273	7.8	5
81	Pulmonary embolism response team implementation improves awareness and education among the house staff and faculty. *Journal of Thrombosis and Thrombolysis*, **2020**, 49, 54-58	5.1	5
80	Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation-a Microsimulation Analysis. *Journal of General Internal Medicine*, **2017**, 32, 464-470	4	4
79	A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia. *Arthritis Care and Research*, **2017**, 69, 1253-1259	4.7	4
78	Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: A mixed-methods study. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 79-84	5.1	4
77	Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. *Journal of Thrombosis and Thrombolysis*, **2019**, 48, 500-505	5.1	4
76	Assessment of a Best Practice Alert and Referral Process for Preprocedure Antithrombotic Medication Management for Patients Undergoing Gastrointestinal Endoscopic Procedures. *JAMA Network Open*, **2020**, 3, e1920548	10.4	4
75	Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 844-848	5.1	4
74	Current Trends in Anticoagulation Bridging for Patients With Chronic Atrial Fibrillation on Warfarin Undergoing Endoscopy. *American Journal of Cardiology*, **2018**, 121, 1548-1551	3	4
73	The changing characteristics of atrial fibrillation patients treated with warfarin. *Journal of Thrombosis and Thrombolysis*, **2015**, 40, 488-93	5.1	4
72	Venous thromboembolism: a collaborative quality improvement model for practitioners, hospitals, and insurers. *Journal of Thrombosis and Thrombolysis*, **2012**, 33, 274-9	5.1	4

71	Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 714-721	5.1	4
70	Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation. *Journal of General Internal Medicine*, **2019**, 34, 583-590	4	3
69	Evaluating the role of clinical pharmacists in pre-procedural anticoagulation management. *Hospital Practice (1995)*, **2018**, 46, 16-21	2.2	3
68	Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. *Circulation: Cardiovascular Quality and Outcomes*, **2016**, 9, 406-13	5.8	3
67	Use of decision aids for shared decision making in venous thromboembolism: A systematic review. *Thrombosis Research*, **2016**, 143, 71-5	8.2	3
66	Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. *American Journal of Cardiology*, **2013**, 112, 387-9	3	3
65	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. *Blood Advances*, **2017**, 1, 2536-2540	7.8	3
64	Anticoagulation: a pathway to clinical effectiveness. *American Journal of Medicine*, **2009**, 122, 126-8	2.4	3
63	Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication. *Blood*, **2019**, 134, 787-787	2.2	3
62	Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. *Implementation Science*, **2020**, 15, 83	8.4	3
61	Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians. *Hamostaseologie*, **2020**, 40, 292-300	1.9	3
60	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. *Journal of Thrombosis and Thrombolysis*, **2016**, 42, 566-72	5.1	3
59	Integrating Lean Thinking and Implementation Science Determinants Checklists for Quality Improvement: A Scoping Review. *American Journal of Medical Quality*, **2020**, 35, 330-340	1.1	3
58	Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 212-220	15.4	3
57	Using Health Systems Engineering Approaches to Prepare for Tailoring of Implementation Interventions. *Journal of General Internal Medicine*, **2021**, 36, 178-185	4	3
56	Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, 253-260	5.1	3
55	Root Cause Analysis of Adverse Events in an Outpatient Anticoagulation Management Consortium. *Joint Commission Journal on Quality and Patient Safety*, **2017**, 43, 299-307	1.4	2
54	How the Results of a Randomized Trial of Catheter-Directed Thrombolysis Versus Anticoagulation alone for Submassive Pulmonary Embolism Would Affect Patient and Physician Decision Making: Report of an Online Survey. *Journal of Clinical Medicine*, **2019**, 8,	5.1	2

53	Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach. *Journal of the American Heart Association*, **2020**, 9, e016949	6	2
52	Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2025-2030	15.4	2
51	Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation. *Journal of Thrombosis and Thrombolysis*, **2018**, 45, 403-409	5.1	2
50	AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative. *Case Reports in Medicine*, **2014**, 2014, 754147	0.7	2
49	Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants. *Hospital Practice (1995)*, **2014**, 42, 62-7	2.2	2
48	Emergency Department Clinician Perceptions of Implementing High-Sensitivity Troponin T Assay in an Academic Hospital Emergency Department. *American Journal of Medicine*, **2020**, 133, e483-e494	2.4	2
47	Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. *Thrombosis Research*, **2021**, 203, 27-32	8.2	2
46	Early career professionals: the mission of a task force. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1328-9	15.4	2
45	Periprocedural Antithrombotic Management from a Patient Perspective: A Qualitative Analysis. *American Journal of Medicine*, **2019**, 132, 525-529	2.4	2
44	Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative Experience. *JAMA Cardiology*, **2017**, 2, 341-343	16.2	1
43	Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey. *Thrombosis Research*, **2019**, 180, 25-27	8.2	1
42	"Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy": Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. *Joint Commission Journal on Quality and Patient Safety*, **2020**, 46, 173-180	1.4	1
41	What you don't know can kill you. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 8-10	5.1	1
40	Sleep apnea and peripheral artery disease: Bringing each other out of the shadows. *Atherosclerosis*, **2016**, 251, 540-541	3.1	1
39	Nation-Wide Use of Periprocedural Bridging Anticoagulation in Patients With Atrial Fibrillation. *American Journal of Cardiology*, **2019**, 124, 1549-1553	3	1
38	Apixaban has Superior Effectiveness and Safety Compared to Rivaroxaban in Patients with Commercial Healthcare Coverage: A Population-Based Analysis in Response to CVS 2022 Formulary Changes.. *American Journal of Hematology*, **2022**,	7.1	1
37	A Comparison of Socioeconomic Factors in Patients Continuing Warfarin Versus Those Transitioning to Direct Oral Anticoagulants (DOACs) for Venous Thromboembolic Disease or Atrial Fibrillation. *Blood*, **2016**, 128, 1179-1179	2.2	1
36	Inpatient Thrombophilia Testing: At What Expense?. *Journal of Hospital Medicine*, **2017**, 12, 777-778	2.7	1

35	Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. *American Journal of Cardiology*, **2021**, 159, 100-106	3	1
34	Trends in Calcium Channel Blocker Use in Patients with Heart Failure with Reduced Ejection Fraction and Comorbid Atrial Fibrillation. *American Journal of Medicine*, **2021**, 134, 1413-1418.e1	2.4	1
33	Restarting antithrombotics after GI bleeding was linked to better outcomes in patients with AF. *Annals of Internal Medicine*, **2016**, 164, JC33	8	1
32	Web Exclusive. Annals for Hospitalists Inpatient Notes - Reaching for Higher Value in Health Care by Bringing Together Clinicians and Researchers-The Michigan Program on Value Enhancement. *Annals of Internal Medicine*, **2019**, 171, HO2-HO3	8	1
31	Inappropriate Prescription of Direct Oral Anticoagulant Starter Packs. *American Journal of Medicine*, **2021**, 134, 370-373.e1	2.4	1
30	Out-of-range INR results lead to increased health-care utilization in four large anticoagulation clinics. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 490-496	5.1	1
29	Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events.. *Vascular Medicine*, **2022**, 1358863X221089333	3.3	1
28	Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study.. *Journal of Thrombosis and Thrombolysis*, **2022**, 1	5.1	1
27	Managing suspected venous thromboembolism when a pandemic limits diagnostic testing. *Thrombosis Research*, **2020**, 196, 213-214	8.2	0
26	Development of a multicomponent implementation strategy to reduce upper gastrointestinal bleeding risk in patients using warfarin and antiplatelet therapy, and protocol for a pragmatic multilevel randomized factorial pilot implementation trial.. *Implementation Science Communications*	2.2	0
25	Implementing an electronic health record dashboard for safe anticoagulant management: learning from qualitative interviews with existing and potential users to develop an implementation process.. *Implementation Science Communications*, **2022**, 3, 10	2.2	0
24	Anticoagulant drug-drug interactions: Highlighting the need for antithrombotic stewardship and shared decision making.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12662	5.1	0
23	The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review. *Current Medical Research and Opinion*, **2021**, 1-12	2.5	0
22	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. *Annals of Internal Medicine*, **2021**, 174, 1490	8	0
21	Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program. *Thrombosis Research*, **2021**, 199, 119-122	8.2	0
20	The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model. *Journal of Medical Economics*, **2021**, 24, 1070-1082	2.4	0
19	Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, **2021**, 52, 214-223	5.1	0
18	Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series. *Journal of Thrombosis and Thrombolysis*, **2021**, 1	5.1	0

17	Early (0-7 day) and late (8-30 day) readmission predictors in acute coronary syndrome, atrial fibrillation, and congestive heart failure patients. *Hospital Practice (1995)*, **2021**, 1-7	2.2	0
16	Predictors of Early (0-7 Days) and Late (8-30 Days) Readmission in a Cohort of Acute Coronary Syndrome Patients.. *International Journal of Medical Students*, **2022**, 10, 38-48	2	0
15	Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study.. *American Heart Journal*, **2022**, 248, 42-42	4.9	0
14	Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients.. *Journal of Pharmacy Practice*, **2021**, 8971900211064189	1.3	0
13	Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.. *Current Cardiology Reports*, **2022**, 1	4.2	0
12	Identifying Clinical Predictors of Switching From Direct Oral Anticoagulants to Warfarin. *Clinical Medicine Insights Therapeutics*, **2019**, 11, 1179559X1983128	0	
11	Anticoagulation in Venous Thromboembolism **2018**, 297-323		
10	Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications. *Reviews in Vascular Medicine*, **2014**, 2, 136-142		
9	Outcomes of Direct Oral Anticoagulants with Aspirin Versus Warfarin with Aspirin for Atrial Fibrillation and/or Venous Thromboembolic Disease. *Blood*, **2021**, 138, 179-179	2.2	
8	A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism. *Blood*, **2019**, 134, 788-788	2.2	
7	Web Exclusives. Annals for Hospitalists Inpatient Notes - Oral Anticoagulation for the Hospitalist-Expanded Choices Improve Patient-Centered Care. *Annals of Internal Medicine*, **2016**, 165, HO2-HO3	8	
6	Response: Patient and caregiver engagement in venous thromboembolism research. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, 247	5.1	
5	Adverse outcomes associated with inappropriate direct oral anticoagulant starter pack prescription among patients with atrial fibrillation: a retrospective claims-based study. *Journal of Thrombosis and Thrombolysis*, **2021**, 51, 1144-1149	5.1	
4	Improving preprocedure antithrombotic management: Implementation and sustainment of a best practice alert and pharmacist referral process. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12558	5.1	
3	To Deprescribe or Not to Deprescribe Aspirin-A Clear Indication Is the Challenge-Reply. *JAMA Internal Medicine*, **2021**, 181, 1541	11.5	
2	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. *American Heart Journal*, **2021**, 242, 71-81	4.9	
1	Maintaining Implementation through Dynamic Adaptations (MIDAS): protocol for a cluster-randomized trial of implementation strategies to optimize and sustain use of evidence-based practices in Veteran Health Administration (VHA) patients.. *Implementation Science Communications*, **2022**, 3, 53	2.2	